Before the Bell Scans: PDL BioPharma Inc., Amgen Inc., Questcor Pharma Inc., and BioCryst Pharma Inc. Editor Note: For more information about this release, please scroll to bottom. PR Newswire LONDON, November 8, 2013 LONDON, November 8, 2013 /PRNewswire/ -- On Thursday, November 07, 2013, all three benchmark indexes of the US equity market posted losses, with the S&P 500, the Dow Jones Industrial Average, and the NASDAQ Composite declining by 1.32%, 0.97%, and 1.90%, respectively. Shares in the biotechnology industry ended on a lower note, tracking losses in the broader market. The major movers in the industry included PDL BioPharma Inc. (NASDAQ: PDLI), Amgen Inc. (NASDAQ: AMGN), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), and BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX). All these companies are tracked by AAAResearchReports.com. Free technical research on PDLI, AMGN, QCOR, and BCRX can be downloaded upon signing up at: http://www.aaaresearchreports.com/register/ PDL BioPharma Inc.'s shares traded between $7.97 and $8.38 before finishing the day 3.35% lower at $8.08. A total of 3.85 million shares were traded, which is above the daily average volume of 1.66 million. Despite Thursday's decline, the company's shares have gained 5.90% in the last one month, outperforming the S&P 500, which has advanced 4.24% during the same period. Further, PDL BioPharma Inc.'s stock is trading above its 50-day and 200-day moving averages of $8.01 and $7.73, respectively. Sign up today to read free research report on PDLI at: www.AAAResearchReports.com/PDLI110813.pdf On Thursday, Amgen Inc.'s stock declined by 2.03%, tracking losses in the broader market. The company's shares traded between $110.65 and $115.25 before finishing the day at $111.03. A total of 3.81 million shares were traded, which is above the daily average volume of 3.21 million. Despite Thursday's pullback, the company's shares have gained 0.73% in the last one month, compared to a gain of 4.24% in the S&P 500 during the same period. Additionally, Amgen Inc.'s stock is trading above its 200-day moving average of $103.46. Register to download free technical analysis on AMGN at: www.AAAResearchReports.com/AMGN110813.pdf On Thursday, shares in Questcor Pharmaceuticals Inc. closed at $58.34, down 4.25% from the previous day's closing price of $60.93. The company's shares vacillated between $57.61 and $61.86 during the trading session. A total of 2.41 million shares were traded, which is above the daily average volume of 1.86 million. Despite Thursday's decline, the company's shares have gained 1.80% in the last one month, compared to a gain of 4.24% in the S&P 500 during the same period. Moreover, Questcor Pharmaceuticals Inc.'s stock is trading above its 200-day moving average of $45.52. A free report on QCOR can be accessed by registering at: www.AAAResearchReports.com/QCOR110813.pdf Shares in BioCryst Pharmaceuticals Inc. fluctuated between $5.04 and $5.45 before ending the Thursday's session 3.33% lower at $5.08. A total of 1.15 million shares were traded, which is below the daily average volume of 1.39 million. The company's shares have plummeted by 10.25% in the previous three trading sessions, compared to a loss of 1.18% in the S&P 500 during the same period. However, BioCryst Pharmaceuticals Inc.'s stock is trading above its 200-day moving average of $3.36. Register with AAA Research Reports and download the research on BCRX for free at: www.AAAResearchReports.com/BCRX110813.pdf ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. SOURCE AAA Research Reports Contact: Phone #: + 1 (646) 396-9126 Contact Name: Peter F. Jones
Before the Bell Scans: PDL BioPharma Inc., Amgen Inc., Questcor Pharma Inc., and BioCryst Pharma Inc.
Press spacebar to pause and continue. Press esc to stop.